期刊
INTERNATIONAL JOURNAL OF PSYCHIATRY IN CLINICAL PRACTICE
卷 16, 期 3, 页码 170-177出版社
TAYLOR & FRANCIS LTD
DOI: 10.3109/13651501.2011.653377
关键词
Bipolar disorder; symptoms; rating scale; prediction
类别
资金
- Stockholm County Council (ALF) [20060306, 20080247]
- Soderstrom-Konigska Foundation
- Bristol-Myers Squibb
- Organon
- Pfizer
- Janssen-Cilag
- AstraZeneca
- Eli Lilly
- Sanofi-Aventis
Objective. The objective of the study was to investigate affective symptoms and pharmacological treatment in bipolar I disorder patients, and to test whether self-rated symptoms could predict hospital admissions during a 12-month follow-up period. Methods. A total of 231 outpatients with clinical bipolar I disorder were recruited. The clinical diagnoses were reassessed by a semi-structured interview. Twenty-four patients (10%) was reclassified as bipolar disorder type II or schizoaffective disorder (bipolar type). Medication status was recorded and symptoms were assessed with the self-rating scale AS-18. Patients were prospectively followed for 12 months and hospitalizations during that time were recorded. Results. More than half (60%) rated themselves as normothymic. Mixed affective symptoms were more common than either depressive or manic/hypomanic symptoms. The admission rate during 1 year of follow-up was 13% (95% C.I.8-17%). Patients which at baseline rated themselves high in either mania or in depression had a significantly increased risk for hospitalization (OR = 3.15; 95% C. I. 1.38-7.19). Conclusions. The findings should encourage clinicians to use patient self ratings in order to identify patients with a high risk for hospitalization for targeted interventions.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据